A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 in the Treatment of Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
Latest Information Update: 09 Apr 2020
At a glance
- Drugs Tegoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors Shandong Luoxin Pharmaceutical
- 07 Apr 2020 Status changed from recruiting to completed.
- 31 Oct 2018 Status changed from not yet recruiting to recruiting.
- 24 Jul 2018 New trial record